G. Rose et al., EVALUATION OF HOUSEHOLD DUST-MITE EXPOSURE AND LEVELS OF SPECIFIC IGEAND IGG ANTIBODIES IN ASTHMATIC-PATIENTS ENROLLED IN A TRIAL OF IMMUNOTHERAPY, Journal of allergy and clinical immunology, 97(5), 1996, pp. 1071-1078
Background: Monitoring the response to immunotherapy entails understan
ding exposure to relevant allergens. For the major indoor allergens, t
his requires sampling of dust from the patient's house. The objectives
of this study were to measure indoor allergen levels during a control
led trial of dust mite immunotherapy for asthma and to relate these re
sults to serum antibody levels. Methods: Eighty-eight asthmatic patien
ts with mite allergy from seven geographic areas in the United States
were enrolled in and completed a course of immunotherapy with Dermatop
hagoides extract or placebo control. Sensitization was evaluated by qu
antitative measurements of IgG and IgE antibodies. Dust samples were a
ssayed for group I mite (Der p I and Der f 1), cat (Fel d 1), and cock
roach (Bin g 1) allergens by monoclonal antibody-based ELISA. Results:
Over the 4 years of the study, each of the houses had at least one sa
mple that contained more than 2 mu g of group I mite allergen pet gram
of dust. Mean mite allergen levels, however varied over a wide range,
from 0.2 mu g/gm or less to more than 50 mu g/gm. IgE antibodies to m
ite were present in sera from 78% of the patients whereas IgE antibodi
es to cat and cockroach allergens were found in sera from 34% and 11%
of patients, respectively. Sixty-four percent of the patients had expo
sure and sensitization to mite, whereas the comparable figure for each
of the other allergens was 5%. Conclusions: Examination of the result
s suggested that allergen exposure, relative to a trial of immunothera
py, could be expressed as (1) the maximum level found in the house, (2
) the percentage of sites having greater than 2 mu g/gm, or (3) the me
an value at the site with the maximum level. This report provides a ba
ckground for evaluating the clinical results of immunotherapy in these
patients and a model for the way in which sensitization and exposure
should be monitored in studies of this kind.